Dong-A Socio Holdings
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dong-A Socio Holdings
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.
After apparent long delays in development, AbbVie returns rights to Dong-A's MerTK program, with the South Korean pharma yet to determine the fate of the still preclinical stage assets.
South Korea is stepping on the gas to develop its own mRNA COVID-19 vaccine and eventually next generation mRNA platform technology for use in other diseases, to meet its goal of becoming a global vaccine hub.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
- OTC, Consumer
In Vitro Diagnostics
- Chemistry, Immunoassay
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Dong-A Pharmaceutical Co., Ltd (Dong-A Pharm)
- Dong-A Science Technology Co., Ltd (Dong-A ST)
- Dong-A Socio Group
- JCOM Co. Ltd.
- Mezzion Co. Ltd.